AKTUAPHARMA
Board
1 office holder, 1 auditor, no change since July 2026Managing director, permanent representative Tomasz Buczek
appointed by deed of 12-08-2011
Statutory auditor, permanent representative Tom Renders
appointed by deed of 12-08-2011
3-year term from 2026
- Docpharma BVBA
- Signing authorityThe articles say who may bind the company, for example by signing a contract.
- Each director alonedeed of 02-07-2026
Permanent representatives 1
Mandates through the years
9 names, the dashed line is todayDocpharma BVBA
Managing director
Managing director
Deloitte Bedrijfsrevisoren/Réviseurs d’Entreprises
Statutory auditor
Statutory auditor
Viatris GX
Director
Director
Gary Elmer SPHAR
Director
Director
Kristin Ann KOLESAR
Director
Director
Seshan Srinivasan
Director
Director
Nimmagadda Prasad
Board
Board
SVR Invest BVBA
Director
Director
Stijn Van Rompay
Director
Director
LeadershipEarlierRest of the termmandate already running before its first mentionend not dated
Mandates as a list
- Docpharma BVBA
- Managing director, appointed by deed of 12-08-2011, until 02-07-2026
- Managing director, appointed by deed of 12-08-2011, still in office
- Director, from before 19-06-2014, ended, last mentioned on 14-07-2020
- Deloitte Bedrijfsrevisoren/Réviseurs d’Entreprises
- Statutory auditor, appointed by deed of 12-08-2011, still in office
- Viatris GX
- Director, appointed by deed of 29-01-2015, until 02-07-2026
- Gary Elmer SPHAR
- Director, appointed by deed of 30-05-2013, until 31-12-2014
- Kristin Ann KOLESAR
- Director, appointed by deed of 12-08-2011, until 06-05-2013
- Seshan Srinivasan
- Director, until 01-07-2011
- Nimmagadda Prasad
- Board, until 01-10-2010
- SVR Invest BVBA
- Director, appointed by deed of 18-09-2006, no longer listed in the 2025 annual accounts
- Stijn Van Rompay
- Director, until 18-11-2005
Control
99.99%
This company
AKTUAPHARMA
Equity -€3.2m
Loss €115,471 in 2025
Further up the chainViatris GX 100%Viatris Inc US consolidates
Capital
- Capital
- €62,000
- Shares
- 1,200 in the 2025 annual accounts
- Contribution per share
- €51.67
- Equity per share
- -€2,652 in 2025
- Source
- deed of 15-02-2024
Owners through the years
as the annual accounts name themOwners as a list
- DOCPHARMA
- Matrix Laboratories
- Viatris Inc
- Mylan N.V.
- Mylan Inc
- Matrix Laboratories Ltd
Source: shareholder structure in its own accounts, parent in its own accounts
Articles of association
deed of 15-02-2024 (in Dutch)- DurationMost companies exist for an unlimited period, until they are dissolved.
- Unlimited
- Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
- Third Thursday of June at 14:00
- Dissolution ruleThe articles set when and by whom the company can be dissolved.
- “Besluit van algemene vergadering die beraadslaagt op wijze door wet vereist,te allen tijde, ontbonden in bij wet bepaalde gevallen”
- Liquidation ruleIn a liquidation the creditors are paid first. What is left goes to the shareholders.
- “Algemene vergadering kan te allen tijde bevoegdheden bij gewone meerderheid beperken, alle machten in artikel 2:87 Wetboek van…”
Shareholders
3 ownersOwners 3
- DOCPHARMAparentEquity €36.6m Profit of €581,444 in 2025 (profit of €1.2m in 2024) Checked score 8899.99%
- Viatris IncUSconsolidating parentconsolidates
- Equity -€16.2m Loss of €27,627 in 2025 (loss of €32,070 in 2024) Checked score 00.01%
Capital transactions
Capital over time
- 15-02-2024 Capital stated in the deed · €62,000 · 120,000 shares
- 15-05-2006 Capital reduction of €1,543,118.97
- 15-05-2006 Capital increase of €43,334.84 · to €62,000 · in cash